Uncovering Potential
Interview with Olivier Lambrechts, executive leadership team member and president NCE at Arxada.
Arxada
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Flow Chemistry
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Investing in Growth Through Innovation
Interview with Marc Doyle, CEO of Arxada, which was created following the carve-out and sale of Lonza Specialty Ingredients to private equity firms Bain Capital and Cinven.
Expert Statement: Ulrich Mayerhoeffer, Arxada
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Arxada Expands at Visp to Continue Supplying DSM
Swiss specialty chemicals company Arxada said it will invest 20 million Swiss francs to expand production at its Visp site following the extension of a long-term supply partnership with DSM.
Arxada and Novoset to Collaborate on Novel Composites
Arxada, the recent specialty chemicals spinoff from Swiss CDMO Lonza, has signed an exclusive license agreement with Novoset covering production and sale of a next generation hydrocarbon-based resin system for telecommunications infrastructure and advanced semiconductor packaging.
Arxada Buys Enviro Tech
In its second deal since becoming an independent company, Arxada – formerly Lonza Specialty Ingredients – has acquired Enviro Tech Chemical Services, a US manufacturer of proprietary and high efficacy antimicrobial and biocidal products. Financial details of the transaction, which closed on Dec. 22, 2021, were not disclosed.
Arxada and Troy Merger Would Add Muscle in Microbial Control
Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since the separation in July. The fledgling company has announced plans to merge with Troy Corporation, a globally oriented US player in microbial control.
